Date: 2013-11-13
Type of information: Fundraising
Company: Antabio (France)
Investors: Bpifrance (France)
Amount: € 742,000
Funding type:
Planned used: With the support of Bpifrance, Antabio will progress its novel antibiotic adjuvant compounds with the goal of commencing IND enabling studies in 2015. Several projects, originating from both Antabio’s internal R&D activities and external opportunities, are being pursued in parallel with the objective of generating a portfolio of small molecule compounds for the treatment of MDR gram-negative bacteria. The starting points for these projects include existing drug-like molecules with promising adjunctive properties and genetically validated targets with robust screening approaches. The best projects will be developed to clinical proof-of-concept (Phase II a) where they will be available for licensing towards commercialization.
Others: * On November 13, 2013, Antabio, a French antibacterial drug discovery company, and Bpifrance, the French public investment bank, announce that Antabio will receive € 742,000 ($ 1,02 million) in funding from Bpifrance to support the discovery, evaluation and development of new adjunctive antibiotic therapies. Within the Bpifrance-supported programme, Antabio will develop compounds targeting key mechanisms of bacterial pathogenicity that will be co-administered with antibiotics to enhance their effectiveness against multi drug-resistant (MDR) gram-negative bacteria that cause severe and life-threatening infections.
Therapeutic area: Infectious diseases
